Asset Details
Do you wish to reserve the book?
Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications
Do you wish to request the book?
Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications
2025
Overview
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. While traditionally viewed through the lens of neuronal dysfunction, emerging evidence highlights the critical role of endothelial dysfunction in HD pathogenesis. This review provides a comprehensive overview of endothelial dysfunction in HD, drawing on findings from both animal models and human studies. Key features of endothelial dysfunction in HD include impaired angiogenesis, altered cerebral blood flow, compromised neurovascular coupling and cerebrovascular reactivity, and increased blood–brain barrier permeability. Genetic factors such as the mutant huntingtin protein, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), Brain-derived neurotrophic factor (BDNF), and the adenosine A2A receptor (ADORA2A) interact to influence endothelial function in complex ways. Various therapeutic approaches targeting endothelial dysfunction, including antioxidants, nitric oxide enhancers, calcium channel blockers, statins, and metformin, have shown promise in preclinical HD models but face translational challenges, particularly regarding optimal timing of intervention and patient stratification. The implications of these findings suggest that reconceptualizing HD as a neurovascular disorder, rather than purely neuronal, could lead to more effective treatment strategies. Future research priorities should include: (1) developing validated vascular biomarkers for disease progression, (2) advancing neuroimaging techniques to monitor endothelial dysfunction in real-time. These directions will be crucial for bridging the current gap between preclinical promise and clinical success in vascular-targeted HD therapeutics.
Publisher
MDPI AG,MDPI
Subject
/ Animals
/ Blood-Brain Barrier - metabolism
/ Blood-Brain Barrier - physiopathology
/ Brain-derived neurotrophic factor
/ Endothelium, Vascular - metabolism
/ Endothelium, Vascular - pathology
/ Endothelium, Vascular - physiopathology
/ Enzymes
/ Humans
/ Huntington Disease - drug therapy
/ Huntington Disease - metabolism
/ Huntington Disease - pathology
/ Huntington Disease - physiopathology
/ Huntington Disease - therapy
/ Materia medica and therapeutics
/ Mutation
/ Neurons
/ Patients
/ Review
